RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells

Abstract Glioblastoma (GBM) is the most common and lethal form of primary brain tumor, characterized by poor prognosis and limited treatment options, with a median survival of only 12 to 15 months post-diagnosis. Despite standard therapeutic protocols involving temozolomide (TMZ) and radiotherapy, e...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Miroslava Kissova, Judit Martinez Segarra, Tobias Solli Iveland, Marthe Vestvik, Erlend Ravlo, Wei Wang, Lars Hagen, Nina-Beate Liabakk, Maria Camara-Quilez, Miquel Arano Barenys, Ole Solheim, Bård Helge Hoff, Eirik Sundby, Magnar Bjørås, Geir Slupphaug, Torkild Visnes, Alessandro Brambilla
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Nature Portfolio 2025-11-01
श्रृंखला:	Scientific Reports
विषय:	GBM High-throughput screening (HTS) Drug screening
ऑनलाइन पहुंच:	https://doi.org/10.1038/s41598-025-25298-5
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!